What is it about?

Patients with solid organ donor grafts have an increased risk for developing various malignancies. Immunotherapy is used for more and more cancer types, but have not been evaluated in patients with solid organ grafts who is using immunosuppressive therapy due to the risk of graft rejection. We have collected all case reports avaliable in the literature in this review article and tried to point out which factors may contribute to graft rejection, and how to avoid them.

Featured Image

Read the Original

This page is a summary of: Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients, Acta Oncologica, June 2018, Taylor & Francis,
DOI: 10.1080/0284186x.2018.1479069.
You can read the full text:

Read

Contributors

The following have contributed to this page